AMRN Related Momentum Movers
-
Amarin (AMRN) Dips Following FDA Orange Book Update
-
Amarin (AMRN) in Focus as Traders Await NCE Decision on Vascepa
-
Amarin (AMRN) Ramps as BASF's Pronova Takeover Highlights Value
-
FDA Says NCE Status on Amarin (AMRN) Has Not Yet Been Determined
-
UPDATE: Amarin (AMRN) Surges; Is It NCE Related?
-
Amarin (AMRN) Drops Most in 7 Months as FDA Makes No Determination on Vascepa
-
Amarin (AMRN) Ticks Lower as NCE Status Called into Question by Noted Biotech Watcher
-
Amarin (AMRN) Upside May Be Related to Conference Cancellation
-
Amarin (AMRN) Said No FDA NCE Decision in August Orange Book
-
Amarin (AMRN) '889 Patent Allowed
-
Amarin (AMRN) Shows Early Strength Following Vascepa Phase 3 Update
-
Amarin (AMRN) Shares Ramp Higher Following Publication of New Vascepa Phase 3 Data
-
Amarin (AMRN) Is 'In Play'
-
Profit Taking in Amarin (AMRN) as Trading Resumes, Shares Around $15
-
Amarin (AMRN) Ramps After Webpage Showing AMR101 FDA Approval
-
Technicians Take Amarin (AMRN) Over $15; Trend Pointing to More Upside
-
Amarin Corporation (AMRN) Sees Upside Action
-
Amarin (AMRN) Shares Active at $14 Level, Remains Above Patent/Analyst Gap Higher
-
Shares of Amarin (AMRN) Plunge as $15 Level Doesn't Hold
-
Amarin (AMRN) Shares Bounce Off Key Level, Holding Over $15
-
Amarin Corp. (AMRN) Shares Pop on Boosted Target, Positive Analyst Comments
-
Amarin (AMRN) Sees Morning Upside
-
Amarin Corporation plc (AMRN) Ramps on Lovaza News
-
Amarin (AMRN) Shares Continue Higher as M&A Chatter Persists, Peer Provides Concerning Phase 3 Data
-
UPDATE: Amarin (AMRN) Shares Pop Higher as Real M&A Speculates on Takeover
-
MKM Reiterates Buy, $20 Target on Amarin (AMRN) Following Application Allowance
-
USPTO Allows Amarin's (AMRN) '598 Application, Investors Cheer
-
Amarin (AMRN) '598 Patent Allowed
-
Amarin (AMRN) Shares Pare Loss as Traders Sell First, Ask Questions Later
-
Amarin (AMRN) Shares Sell Off Following 30+% Surge Over Last Three Trading Sessions
-
USPTO Revises Transaction History for Amarin's (AMRN) '598 Patent to 'Document Verification'
-
Amarin Corporation (AMRN) Sees Continued Upside
-
Amarin (AMRN) Shares Rally as USPTO Updates Transaction History for '598 Patent, Leerink Calls Co. 'Prime' Takeover Target
-
Amarin (AMRN) Gives Back 6%+ Gains, Now Slightly Lower
-
Shares of Amarin (AMRN) Plunge as USPTO Issues Non-Final Rejection for 13/284,408 Patent
-
Amarin (AMRN) Shares Sink 8% Over Last Few Minutes
-
Amarin Corporation (AMRN) Sees Upside Action
-
Amarin (AMRN) Shares Sink in Afternoon Trade, Now Down 6%
-
Amarin (AMRN) Higher On Reports of a Possible Sale
-
Amarin (AMRN) Gives Back Some of Yesterday's 95% Gains
-
Amarin (AMRN) Surges Following Statistically Significant Study of AMR101
-
Amarin (AMRN) AMR101 MARINE Phase 3 Trial Meets Endpoints
Back to AMRN Stock Lookup
